This study aimed to identify novel prognostic factors for Morbihan disease (MD) treatment outcomes and evaluate the efficacy of combination therapy in an Asian population, addressing the gaps in current unders... … [Read more...] about Novel prognostic factors and combination therapy outcomes in Morbihan disease: insights from an Asian population
News
VIDEO: Technology needed to measure impact of geographic atrophy treatment
November 12, 2024 1 min watch NEW YORK — In this Healio Video Perspective from OSN New York Retina, Lejla Vajzovic, MD, FASRS, of Duke Eye Center in Durham, North Carolina, discusses the adoption of therapies for the treatment of geographic atrophy. “There is a big need for identifying technologies that will not only help us identify patients who will benefit but also … [Read more...] about VIDEO: Technology needed to measure impact of geographic atrophy treatment
MediPrint Ophthalmics reveals positive results from phase 2b study of LL-BMT1 contact lens
MediPrint Ophthalmics announced results from the company’s phase 2b clinical trial of LL-BMT1 at this year’s American Academy of Optometry meeting in Indianapolis.LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens created by the company’s proprietary 3D printing technology, that delivers a sustained dose of bimatoprost and hyaluronic acid for the treatment … [Read more...] about MediPrint Ophthalmics reveals positive results from phase 2b study of LL-BMT1 contact lens
VIDEO: Johnson & Johnson Vision shares update on cataract, refractive armamentarium
November 12, 2024 3 min watch CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Xiao-Yu Song, MD, PhD, of Johnson & Johnson Vision, gives an overview of company innovations for improving vision outcomes in refractive and cataract surgery. Song discussed the Tecnis series of IOLs, which she said are designed “to deliver the best-in-class contrast and … [Read more...] about VIDEO: Johnson & Johnson Vision shares update on cataract, refractive armamentarium
HuidaGene Therapeutics’ IND application for HG202 for the treatment of nAMD cleared by FDA
The US FDA has cleared an investigational new drug (IND) application for HG202, by HuidaGene Therapeutics. This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD).Alvin Luk, PhD, MBA, CCRA, the co-founder and CEO of HuidaGene is quoted in the company’s press release noting this … [Read more...] about HuidaGene Therapeutics’ IND application for HG202 for the treatment of nAMD cleared by FDA
VIDEO: EYP-1901 shows positive vision, treatment burden outcomes at 1 year
November 12, 2024 6 min watch CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Carl D. Regillo, MD, FACS, of Wills Eye Hospital, shares study results from the phase 2 DAVIO 2 trial. The trial investigated EYP-1901 (vorolanib, EyePoint Pharmaceuticals) as a treatment for wet age-related macular degeneration at 12 months … [Read more...] about VIDEO: EYP-1901 shows positive vision, treatment burden outcomes at 1 year
Harrow announces expanded market access for cyclosporine ophthalmic solution in 2025 Medicare Part D Program
Harrow today announced new market access achievements in the 2025 Medicare Part D Prescription Drug Program.According to the company, effective January 1, 2025, cyclosporine ophthalmic solution 0.1% (Vevye) will be included on key formularies managed by major plan sponsors, including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. Collectively, these plan sponsors … [Read more...] about Harrow announces expanded market access for cyclosporine ophthalmic solution in 2025 Medicare Part D Program
Study explores the true costs of treating pediatric cataracts
Reviewed by Vinita Rangroo Thrane, MD, PhD; Alexander S. Thrane, MD, PhD, FEBOphth; and Nils-Erik Boonstra, MDPediatric cataracts are a leading cause of reversible childhood blindness, but economic constraints make treatment challenging for many patients worldwide. In a presentation at the 42nd Congress of the European Society of Cataract and Refractive Surgeons, Vinita Rangroo … [Read more...] about Study explores the true costs of treating pediatric cataracts
Management of persistent exudative retinal detachment: exploring etiology and surgical outcomes
This report aims to present the causes, clinical features, and surgical outcomes of persistent exudative retinal detachment (ERD) in a single tertiary referral center experience. … [Read more...] about Management of persistent exudative retinal detachment: exploring etiology and surgical outcomes
Evaluation of ocular surface inflammation and systemic conditions in patients with systemic lupus erythematosus: a cross-sectional study
The cross-sectional study was designed to evaluate the association of ocular surface inflammation with systemic conditions in patients with systemic lupus erythematosus (SLE). … [Read more...] about Evaluation of ocular surface inflammation and systemic conditions in patients with systemic lupus erythematosus: a cross-sectional study